Key result
Bevacizumab combined with chemotherapy or biological therapy increased the risk of fatal adverse events compared with chemotherapy alone (2.5% vs 1.7%; RR 1.46; 95% CI 1.09-1.94; P=.01).
Why the study?
Does bevacizumab in combination with chemotherapy or biological therapy increase the risk of fatal adverse events in patients with advanced solid tumors?
Population
10,217 patients with a variety of advanced solid tumors from 16 RCTs
Comparison
Bevacizumab in combination with chemotherapy or… vs Chemotherapy or biological therapy alone
Design
Meta-analysis
Authors
Loading...
Bevacizumab regimens warrant explicit mortality risk discussion in advanced solid tumors; confirms elevated fatal events across pooled RCTs.
Meta-Analysis (n=10,217)
Does bevacizumab in combination with chemotherapy or biological therapy increase the risk of fatal adverse events in patients with advanced solid tumors?
Relative Risk: 1.46 (95% CI 1.09–1.94)
Absolute Event Rate: 2.5% vs 1.7%
p-value: p=.01
The addition of bevacizumab to chemotherapy or biological therapy in patients with advanced solid tumors is associated with a significantly increased risk of treatment-related mortality.
Ranpura et al. (2011) conducted a meta-analysis in advanced solid tumors (n=10,217). Bevacizumab in combination with chemotherapy or biological therapy vs. Chemotherapy or biological therapy alone was evaluated on Fatal adverse events (FAEs) (RR 1.46, 95% CI 1.09-1.94, p=.01). Bevacizumab combined with chemotherapy or biological therapy increased the risk of fatal adverse events compared with chemotherapy alone (2.5% vs 1.7%; RR 1.46; 95% CI 1.09-1.94; P=.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: